Sorafenib: a promising new targeted therapy for renal cell carcinoma.

@article{Wood2007SorafenibAP,
  title={Sorafenib: a promising new targeted therapy for renal cell carcinoma.},
  author={Laura S. Wood and Beth Manchen},
  journal={Clinical journal of oncology nursing},
  year={2007},
  volume={11 5},
  pages={649-56}
}
Diagnosis of renal cell carcinoma (RCC) frequently occurs at advanced stages, severely limiting the success of treatment, and median survival is barely more than a year. Previously, treatment of renal cancer was limited to nephrectomy or immunotherapy (interleukin or interferon-alpha), which was effective in a small subset of patients but often was accompanied by severe side effects. New orally administered targeted therapies have become available, offering broader benefits to patients with… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
DiarrheaNo subtypeFatigue
This article reviews the management of skin rash , hand - foot skin reaction , hypertension , diarrhea , and fatigue in patients receiving sorafenib .
FatigueNo subtypeDiarrhea
This article reviews the management of skin rash , hand - foot skin reaction , hypertension , diarrhea , and fatigue in patients receiving sorafenib .
All Topics